SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Sun Yat-sen — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSun Yat-sen
Date of birth1866-11-12
IdentifiersMRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183
Document date1924-08-03
AuthorWen-Li Huang, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Before cycle 4: restaging CT, tumor marker, side effects, and genomic profiling result. [S]

History of Present Illness

Mr. Sun returns before cycle 4, nine weeks after starting treatment. He has had all three cycles on schedule. He is nauseated on the two days after each infusion, which ondansetron controls, and tired for three or four days after each day-8 dose; otherwise he works most days. He has no diarrhea, rash, cough or breathlessness, no numbness or tingling, and no ringing in the ears or change in hearing. The ache under his ribs is 1 to 2 of 10 and he takes acetaminophen only a few times a week. He has seen the palliative care team twice and says it helped him sleep and think about his priorities. The restaging CT four days ago and the HBV DNA drawn with it are back, and so is the genomic profiling of his tumor. [S]

ElementDetail
CyclesThree, all on schedule
Side effectsNausea two days after infusions, controlled; tiredness after day-8 doses
Immune-related symptomsNone
Pain1 to 2 of 10; acetaminophen a few times a week
Palliative careTwo visits; sleep and coping better

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired after day-8 doses; weight 59.2 kg; no fever
GastrointestinalPositiveNausea for two days after infusions; no diarrhea or jaundice
Ears, nose, mouth, and throatNegativeNo tinnitus or hearing change; no mouth sores
RespiratoryNegativeNo cough or breathlessness
IntegumentaryNegativeNo rash or itching
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeMood steadier; sleeping better; PHQ-9 5

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a dayTwo tablets by mouth every 8 hours as needed, no more than 3,000 mg a dayOral route1924-05-04activeS
Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cyclesIntravenous route1924-06-01activeS
Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cycles, with hydrationIntravenous route1924-06-01activeS
Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycleDay 1 of each 21-day cycle with chemotherapy, then every 4 weeks aloneIntravenous route1924-06-01activeS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet by mouth every 8 hours as needed for nauseaOral route1924-06-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1924-08-03Body height165cmS
1924-08-03Body weight59.2kgS
1924-08-03Body mass index (BMI) [Ratio]21.7kg/m2S
1924-08-03Systolic blood pressure122mm[Hg]S
1924-08-03Diastolic blood pressure78mm[Hg]S
1924-08-03Heart rate82/minS
1924-08-03Respiratory rate16/minS
1924-08-03Body temperature36.6CelS
1924-08-03Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1924-08-03Leukocytes [#/volume] in Blood by Automated count4.610*3/uL4-11 10*3/uLNormalS
1924-08-03Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.8-7.7 10*3/uLNormalS
1924-08-03Hemoglobin [Mass/volume] in Blood10.9g/dL13.2-17.1 g/dLLowS
1924-08-03Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
1924-08-03Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
1924-08-03Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1924-08-03Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.74-1.35 mg/dLNormalS
1924-08-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M97mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-08-03Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1924-08-03Magnesium [Mass/volume] in Serum or Plasma1.7mg/dL1.7-2.2 mg/dLNormalS
1924-08-03Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
1924-08-03Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.2-1.2 mg/dLNormalS
1924-08-03Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma158U/L40-129 U/LHighS
1924-08-03Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L10-40 U/LNormalS
1924-08-03Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-55 U/LNormalS
1924-08-03Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.45-4.5 mIU/LNormalS
1924-08-03Cancer Ag 19-9 [Units/volume] in Serum or Plasma168U/mL<=35 U/mLHighS
1924-08-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1924-08-03ECOG Performance Status score1{score}S

Physical Exam

Vital signs recorded on 1924-08-03; see the Vital Signs section. [S]

SystemFinding
GeneralThin, well; blood pressure 122/78, pulse 82; weight 59.2 kg; no jaundice
AbdomenLiver edge firm, 3 cm below the right costal margin, smaller than at diagnosis; no ascites
SkinNo rash; port site clean
NeurologicalLight touch and vibration normal in the fingers and toes

Problems

ProblemClinical statusVerificationCodeProvenance
Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arrangedresolvedconfirmed R19.01S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis.
Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinomaactiveconfirmed C23S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy.
Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitoredactiveconfirmed Z86.19S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis.
Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectableactiveconfirmed C78.6S — Synthetic finding anchored to the peritoneal metastases reported at autopsy.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingCT of the chest, abdomen and pelvisAt staging, then every 2 to 3 months on treatmentCompleted todayFour days ago: mass 5.6 cm from 7.1 cm; nodes and peritoneal nodules smaller; no new lesions; stable disease, sum down 24%
LaboratoryCA 19-9 (and CEA when raised)At diagnosis, then with each cycle or restagingCompleted todayCA 19-9 168 U/mL, from 498
LaboratoryBlood count with neutrophilsBefore every dose (days 1 and 8)Completed todayWhite cells 4.6, neutrophils 2.4, hemoglobin 10.9 g/dL (grade 1 anemia), platelets 188; adequate for treatment
LaboratoryCreatinine and eGFRBefore every dose (days 1 and 8)Completed todayCreatinine 0.92 mg/dL, eGFR 97
LaboratoryMagnesium and potassiumBefore every dose (days 1 and 8)Completed todayMagnesium 1.7 mg/dL (lower limit), potassium 4.0 mmol/L, sodium 136 mmol/L; dietary magnesium advised
LaboratoryLiver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin)Before every dose (days 1 and 8)Completed todayBilirubin 0.7 mg/dL, alkaline phosphatase 158, AST 34, ALT 30 U/L, albumin 3.6 g/dL; improving
LaboratoryTSHBaseline, then every 4 to 6 weeks on durvalumabCompleted today2.4 mIU/L
LaboratoryGlucoseBaseline, then with each pre-dose chemistry panel on durvalumabCompleted today94 mg/dL; on the standing pre-dose order since cycle 1 day 8, after the gap at cycle 1 day 1
LaboratoryHBV DNA and ALT (resolved hepatitis B)Every 3 months during treatment and for 6 to 12 months afterCompleted todayHBV DNA undetectable four days ago; ALT 30 U/L
Medication safetyImmune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms)Every visitCompleted todayNo diarrhea, rash, cough, breathlessness or endocrine symptoms
Medication safetyChemotherapy side effects: nausea, fatigue, neuropathy, hearingEvery visitCompleted todayGrade 1 nausea and fatigue; no neuropathy
ExaminationHearing (cisplatin)Baseline before cisplatin, then by symptoms each cycleCompleted todayNo tinnitus or hearing change; whispered voice heard
SurveyECOG performance statusEvery visitCompleted todayECOG 1
ExaminationWeight and nutritionEvery visitCompleted today59.2 kg, 0.8 kg below the start of treatment
SurveyPainEvery visitCompleted today1 to 2 of 10
SurveyDistress and depression (PHQ-9)At each change in treatment or statusCompleted todayPHQ-9 5
LaboratoryComprehensive genomic profiling of tumor tissueAt diagnosis of advanced diseaseCompleted todayNo targetable alteration; microsatellite stable
ReferralSpecialist palliative careFrom the diagnosis of advanced cancerCompleted todayTwo visits; ongoing every 3 to 4 weeks

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)

Follow-up: Cycles 4 to 7 as scheduled. Visit before cycle 8 with a restaging CT, HBV DNA and ALT. Next scheduled visit 1924-09-21: periodic adult preventive visit. [S]